Viktoriya Stalbovskaya

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

Claire Harrison, Jean‐Jacques Kiladjian, Haifa Kathrin Al‐Ali et al. · New England Journal of Medicine · 2012 · 1.8K citations · Full text

Medicine, Hematology, Pharmacology +10

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

Claire Harrison, Alessandro M. Vannucchi, Haifa Kathrin Al‐Ali et al. · Leukemia · 2016 · 509 citations · Full text

Medicine, Hematology, Pharmacology +13

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

Francisco Cervantes, Alessandro M. Vannucchi, Jean‐Jacques Kiladjian et al. · Blood · 2013 · 425 citations · Full text

Medicine, Hematology, Pharmacology +4

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis

Alessandro M. Vannucchi, H. Kantarjian, Jean‐Jacques Kiladjian et al. · Haematologica · 2015 · 253 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study

Paola Guglielmelli, Flavia Biamonte, Giada Rotunno et al. · Blood · 2014 · 129 citations · Full text

Medicine, Hematology, Oncology +15